Clinical trialPhase 2Withdrawn
Adavosertib and Gemcitabine in Advanced Pancreatic
Phase 2 Single Arm Trial Testing Adavosertib and Gemcitabine in Platinum-Resistant Advanced Pancreatic Adenocarcinoma
- Outcome
- Stopped earlymanufacturer choice (Other)
- Phase
- Phase 2
- Status
- Withdrawn
- Study type
- Interventional
- Start
- June 2022
- Expected end
- 31 December 2023
- Enrollment
- 0 participants
- Sites
- 0
- Primary outcomes
- Overall Response Rate (ORR)
- Sponsor
- Other
- Results posted
- No
- Last update
- 14 June 2022
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
This study is being done to test the safety and effectiveness of combining Adavosertib and Gemcitabine in patients with pancreatic cancer. The names of the study drugs involved in this study are: * Adavosertib * Gemcitabine
Detailed description public domain (ClinicalTrials.gov)
This is an open label, single arm phase 2 trial evaluating adavosertib combined with gemcitabine in platinum-resistant advanced pancreatic cancer. Laboratory studies suggest that adavosertib and gemcitabine can impair the growth of cancers by interfering with the way cancer cells repair their DNA. The U.S. Food and Drug Administration (FDA) has not approved adavosertib as a treatment for any disease. The U.S. Food and Drug Administration (FDA) has approved gemcitabine as a treatment option for pancreatic cancer. The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits. It is expected that about 32 people will take part in this research study. The Lustgarten Foundation for Pancreatic Research and Stand Up to Cancer are supporting this research study by providing funding to conduct the study. AstraZeneca, a pharmaceutical company, is supplying the study drug, Adavosertib.